Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemoradiation for Locally Advanced NSCLC
NCT00492206Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Jun 2006
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by University of Pittsburgh. Primary endpoint: Overall Survival at 36 months. Started Jun 2006; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00492206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492206.